January 2024

The license is exclusive for the territory of Japan and contains rights for future indications Maruho is responsible for conducting and bearing costs for development in Japan, which will be conducted jointly with AOB Pharma as part of a Global Phase 3 Study for Atopic Dermatitis encompassing Japan,

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: